Trials / Completed
CompletedNCT06699914
A Study to Evaluate Real-world Brolucizumab Effectiveness and Safety in Japanese Patients With Neovascular Age-related Macular Degeneration (nAMD)
A Retrospective, 12-month, Multicenter Study to Evaluate Real-world Brolucizumab Effectiveness and Safety in Japanese Patients With Neovascular Age-related Macular Degeneration (nAMD) - the PHEASANT Study - a Study Following the Master Protocol
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 438 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
A retrospective, observational, single-arm, non-randomized cohort study of ocular treatment in nAMD patients in Japan who had records of at least 12 months of follow-up after their first brolucizumab intravitreal injection. Patients who had records of at least 12 months of visits after the first brolucizumab injection (index date) were identified during the index period and were recruited during the data collection/recruitment period.
Conditions
Timeline
- Start date
- 2022-09-06
- Primary completion
- 2023-12-01
- Completion
- 2023-12-01
- First posted
- 2024-11-21
- Last updated
- 2024-11-21
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT06699914. Inclusion in this directory is not an endorsement.